证券代码：301130 证券简称：西点药业 公告编号：2025-027 吉林省西点药业科技发展股份有限公司 第八届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 吉林省西点药业科技发展股份有限公司（以下简称"公司"）第八届董事会 第十一次会议于 2025 年 4 月 22 日 9:30 以现场结合通讯方式在吉林省长春市卫 星路 1471 号公司会议室召开。本次会议通知于 2025 年 4 月 12 日以邮件、电话、 书面等方式送达全体董事。会议由董事长张俊先生主持，应出席董事 9 名，实际 出席董事 9 名，其中以通讯方式参会并表决的董事有孟永宏先生、刘淑敏女士、 申太根先生。 公司监事、高级管理人员、保荐代表人列席了会议。 会议的召开符合《中华人民共和国公司法》和《公司章程》的规定，会议合 法有效。 二、会议审议情况 经与会董事认真审议并表决，审议了如下事项： （一）审议通过《关于公司<2024 年度董事会工作报告>的议案》 根据公司董事会 2024 年度工作情况及公司年度经营状况，董事会作出了 《2024 年度 ...

证券代码：301130 证券简称：西点药业 公告编号：2025-029 1、董事会审议情况 公司于 2025 年 4 月 22 日召开第八届董事会第十一次会议，以 9 票同意、0 票反对、0 票弃权的表决结果审议通过了《关于公司<2024 年度利润分配预案>的 议案》，同意该利润分配预案提交公司 2024 年年度股东大会审议。 2、监事会审议情况 吉林省西点药业科技发展股份有限公司 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 1、吉林省西点药业科技发展股份有限公司（以下简称"公司"）2024 年度 利润分配预案为：向全体股东每 10 股派发现金股利 2.60 元人民币（含税），不 转增股本，不送红股。 2、公司 2024 年度利润分配预案不触及《深圳证券交易所创业板股票上市规 则》第 9.4 条第（八）项规定的可能被实施其他风险警示情形。 一、审议程序 自 2025 年 1 月 1 日至实施 2024 年度权益分派的股权登记日期间，公司总股 本发生变动的，拟维持每 10 股派 2.60 元（含税）比例不变，相应 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥52,219,200.85, a decrease of 21.72% compared to ¥66,705,459.25 in the same period last year[5] - Net profit attributable to shareholders was ¥8,294,245.85, down 40.94% from ¥14,042,843.67 year-on-year[5] - Basic and diluted earnings per share were both ¥0.1084, representing a decline of 37.63% from ¥0.1738 in the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥7,567,590.00, down 37.26% from ¥12,061,082.58 year-on-year[5] - The weighted average return on equity was 0.88%, down from 1.42% in the previous year[5] - Net profit for the current period is 7,651,948.96, a decrease of 45.5% compared to 14,042,843.67 in the previous period[24] - Operating profit for the current period is 8,862,074.91, down 45.4% from 16,305,235.17 in the previous period[24] - Total comprehensive income for the current period is 7,651,948.96, compared to 14,042,843.67 in the previous period[24] Cash Flow and Assets - The net cash flow from operating activities increased by 76.53% to ¥13,143,660.17, compared to ¥7,445,732.65 in the previous year[5] - The company's cash and cash equivalents decreased to ¥131,726,829.02 from ¥190,678,612.90, reflecting a decline of approximately 30.9%[18] - The company's total liabilities decreased to ¥95,432,165.64 from ¥121,411,576.83, representing a reduction of approximately 21.4%[20] - The ending cash and cash equivalents balance is 131,165,469.74, down from 286,157,567.56 in the previous period[26] - Cash flow from operating activities shows a net increase of 13,143,660.17, up from 7,445,732.65 in the previous period[26] - Investment cash inflow is 285,316,977.35, compared to 238,619,544.48 in the previous period, indicating a significant increase[26] - Cash flow from investment activities shows a net outflow of 71,884,685.94, contrasting with a net inflow of 6,267,827.88 in the previous period[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,165[11] - The largest shareholder, Zhang Jun, holds 25.66% of the shares, totaling 19,627,034 shares[11] - The top 10 unrestricted shareholders include Dingdian Investment Management (Beijing) Co., Ltd. with 6,013,154 shares, Zhang Jun with 4,906,759 shares, and Zhuhai Hengqin Rock Health Technology Co., Ltd. with 3,697,400 shares[12] - The total number of restricted shares held by major shareholders decreased from 22,838,309 to 17,869,050 shares, with 4,969,259 shares released during the period[14] - The company has a consistent action relationship among its major shareholders, including Dingdian Investment Management and Hengqin Runhui Equity Investment Fund[13] - The company reported a 4.83% stake held by Zhuhai Hengqin Rock Health Technology Co., Ltd., amounting to 3,697,400 shares[12] - The company’s major shareholders include Guotou High-tech Investment Co., Ltd. with a 4.25% stake, equivalent to 3,248,997 shares[12] - The company’s major shareholder, Shi Shilin, holds 1,555,900 shares through a margin trading account[13] - The company’s major shareholder, Meng Yonghong, holds 1,032,187 shares, all of which are subject to lock-up[14] - The company’s major shareholder, Zhejiang Yinwan Private Fund Management Co., Ltd., holds 1,362,300 shares through a margin trading account[13] - The company’s total number of unrestricted shares held by the top 10 shareholders is 22,838,309 shares[14] Operational Highlights - The company reported non-recurring gains of ¥726,655.85, primarily from investment income and fair value changes[6] - The company received approval notifications from the National Medical Products Administration for sodium hyaluronate eye drops, ambroxol oral solution, and antiviral tablets during the reporting period[15] - The company obtained an invention patent for the application of Ruixiangsu in the preparation of drugs for treating viral pneumonia on February 11, 2025[17] - The company completed the registration of capital reduction and obtained a new business license on February 24, 2025, reflecting the updated registered capital[18] - The company's inventory increased slightly to ¥28,615,285.00 from ¥27,972,598.48, showing a growth of about 2.3%[19] Revenue and Costs - Total operating costs for the current period were ¥45,150,013.49, down about 14.7% from ¥52,927,049.86 in the previous period[22] - Total revenue from operating activities is 70,019,820.76, slightly decreased from 70,278,576.60 in the previous period[25] - The company reported a net profit margin decline due to reduced revenue and increased operational costs, impacting overall profitability[22]

Financial Performance - The company's operating revenue for 2024 reached ¥256,405,243.38, representing a year-on-year increase of 13.71% compared to ¥225,491,234.57 in 2023[22]. - The net profit attributable to shareholders decreased by 20.26% to ¥40,268,798.73 in 2024 from ¥50,502,418.80 in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 22.51% to ¥34,746,419.71 in 2024 from ¥28,361,905.28 in 2023[22]. - The total assets at the end of 2024 were ¥1,062,575,503.79, a slight decrease of 0.43% from ¥1,067,195,971.50 at the end of 2023[22]. - The basic earnings per share for 2024 was ¥0.5173, down 17.23% from ¥0.6250 in 2023[22]. - The company reported a cash flow from operating activities of ¥54,243,962.92 in 2024, a marginal decrease of 0.26% compared to ¥54,385,940.66 in 2023[22]. - The company achieved a significant 230.89% increase in other business revenue, rising to ¥1,158,270.72 from ¥350,042.48[72]. - The company's total revenue for 2024 reached ¥256,405,243.38, representing a year-on-year increase of 13.71% compared to ¥225,491,234.57 in 2023[70]. - The main pharmaceutical business generated ¥255,246,972.66, accounting for 99.55% of total revenue, with a growth of 13.37% from ¥225,141,192.09 in the previous year[72]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 2.60 RMB per 10 shares (including tax) to all shareholders[5]. - The total amount for cash dividends and share repurchases in 2024 is expected to be ¥119,886,167.24, representing 297.71% of the net profit attributable to the parent company[197]. - The company plans to distribute a total of ¥391,715,762.62 as available profit for distribution in 2024[195]. Risks and Challenges - The company emphasizes potential risks including policy risks from pharmaceutical system reforms and fluctuations in raw material drug supply and prices[5]. - Environmental protection requirements are increasing operational costs, with potential penalties for non-compliance posing significant risks to production[142]. - Fluctuations in raw material prices, particularly for chemical and traditional Chinese medicine ingredients, could adversely affect the company's profit margins and operational stability[143]. Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, enhancing transparency and accountability in its operations[150]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards and effective oversight[153]. - The company has implemented specialized committees to enhance governance, including audit, compensation, and strategic committees, which adhere to legal requirements[154]. - The company has a supervisory board consisting of 5 members, complying with legal requirements and effectively overseeing major matters and financial conditions[155]. - The company emphasizes information disclosure and investor relations, ensuring timely and accurate information is available to all shareholders and investors[156]. Research and Development - The company is focused on expanding its product pipeline in iron supplements and raw materials, aiming to deepen market penetration and enhance brand influence[35]. - The company has 25 registered formulations (32 specifications) and 16 active pharmaceutical ingredient (API) registrations, focusing on anemia treatment, circulatory disorders, and mental health medications[40]. - Research and development expenses increased by 17.52% to ¥10,224,075.45, indicating ongoing investment in innovation[84]. - The company is developing calcium citrate raw materials, with ongoing large-scale production process validation and stability testing for 12 and 18 months, aiming for industrialization and increased sales scale in the raw material market[85]. Market Position and Strategy - The company is positioned in the pharmaceutical manufacturing sector, focusing on the research, production, and sales of chemical drug raw materials and formulations[31]. - The company actively participates in national and regional centralized procurement activities, expanding its market share through competitive pricing and compliance with procurement responsibilities[36]. - The company aims to optimize production processes continuously to ensure high standards and consistency in both APIs and formulations[43]. - The company is committed to complying with new regulations aimed at improving drug pricing transparency and fairness, which may positively impact its market positioning[38]. Employee and Management - The company has a strong commitment to quality management, with a dedicated Quality Director overseeing operations[172]. - The company has a structured approach to compensation, involving human resources and finance departments in the implementation of salary schemes[177]. - The company has a total of 320 employees at the end of the reporting period, with 270 in the parent company and 50 in major subsidiaries[187]. - The company emphasizes the importance of compliance and risk control, establishing a risk warning mechanism to mitigate potential losses[134]. Acquisitions and Investments - The company completed the acquisition of 58.26% of Shuangsheng Pharmaceutical, which will be included in the consolidated financial statements starting December 2024[199]. - The integration of Shuangsheng Pharmaceutical is part of the company's broader strategy for market expansion and product development[199]. - The company has committed to using the raised funds for specific investment projects as promised[109]. Future Outlook - In 2025, the company plans to focus on "innovation-driven, value reshaping, and digital empowerment" as its strategic core, embracing AI pharmaceuticals and green manufacturing to strengthen its competitive edge[118]. - The company aims to enhance its integrated "API + formulation" advantage, optimizing product structure and achieving collaborative development across the industry chain to improve operational efficiency and economic benefits[118].

国泰海通证券股份有限公司 关于吉林省西点药业科技发展股份有限公司 1 | 1.是否按照相关规定建立内部审计制度并设立内部审计部门（如 | √ | | --- | --- | | 适用） | | | 2.是否在股票上市后六个月内建立内部审计制度并设立内部审计 | √ | | 部门（如适用） | | | 3.内部审计部门和审计委员会的人员构成是否合规（如适用） | √ | | 4.审计委员会是否至少每季度召开一次会议，审议内部审计部门 | √ | | 提交的工作计划和报告等（如适用） | | | 5.审计委员会是否至少每季度向董事会报告一次内部审计工作进 | √ | | 度、质量及发现的重大问题等（如适用） | | | 6.内部审计部门是否至少每季度向审计委员会报告一次内部审计 | | | 工作计划的执行情况以及内部审计工作中发现的问题等（如适 | √ | | 用） | | | 7.内部审计部门是否至少每季度对募集资金的存放与使用情况进 | √ | | 行一次审计（如适用） | | | 8.内部审计部门是否在每个会计年度结束前二个月内向审计委员 | √ | | 会提交次一年度内部审计工作计划（如适用） | | | ...

2025 年度持续督导培训情况报告 根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监 管指引第 13 号——保荐业务》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》要求，国泰海通证券股份有限公司（以下简称"国 泰海通"）作为吉林省西点药业科技发展股份有限公司（以下简称"西点药业"或 "公司"）首次公开发行股票并在创业板上市的保荐机构，对公司进行了 2025 年 度持续督导培训，报告如下： 一、本次培训的基本情况 （一）保荐人：国泰海通证券股份有限公司 国泰海通证券股份有限公司 关于吉林省西点药业科技发展股份有限公司 保荐人本次持续督导培训的工作过程中，公司积极予以配合，保证了培训工 作的有序进行，达到了良好效果。 四、本次培训的结论 通过本次培训，公司相关人员对上市公司规范运作相关法律法规有了更加深 刻的理解与认识，有助于提高公司的规范运作和信息披露水平，本次培训达到了 预期效果。 （六）培训对象：公司控股股东及实际控制人、董事、高级管理人员、部分 关键岗位人员 本次培训前，国泰海通编制了培训材料，并提前要求西点药业参与培训的相 关人员了解培训相关内容。 二、本 ...

证券代码：301130 证券简称：西点药业 公告编号：2025-023 吉林省西点药业科技发展股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回 并继续进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 型 募集 资金 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 1 月 20 日召开第八届董事会第十次会议、第八届监事会第十次会议，分别审议通 过了《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现 金管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和 资金安全的前提下，使用额度不超过人民币 1.0 亿元的部分闲置募集资金（含超 募资金）进行现金管理，公司及全资子公司在确保不影响公司日常经营的前提下， 使用额度不超过人民币 1.5 亿元的部分闲置自有资金进行现金管理和委托理财， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自董事会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可循 环滚动使用。具体内容详见公司在巨潮资讯网上披露的《关 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301130 证券简称：西点药业 公告编号：2025-022 吉林省西点药业科技发展股份有限公司 关于公司抗病毒片获得药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 吉林省西点药业科技发展股份有限公司关于公司抗 病毒片获得药品补充申请批准通知书的公告 生产企业地址：吉林省吉林市磐石市英联大街777号 证书编号：2025B01062 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局（以下简 称"国家药监局"）签发的抗病毒片《药品补充申请批准通知书》。现将相关情况公告如下： 一、药品的基本情况 药品名称：抗病毒片 剂型：片剂 规格：薄膜衣片:每片重0.32g 注册分类：中药 上市许可持有人：吉林省西点药业科技发展股份有限公司 上市许可持有人地址：吉林省磐石经济开发区西点大街777号 生产企业：磐石巨康药业有限公司 药品批准文号：国药准字Z19991079 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品此次申请事项符合药品注 ...

证券代码：301130 证券简称：西点药业 公告编号：2025-022 吉林省西点药业科技发展股份有限公司 药品名称：抗病毒片 剂型：片剂 规格：薄膜衣片:每片重 0.32g 注册分类：中药 上市许可持有人：吉林省西点药业科技发展股份有限公司 上市许可持有人地址：吉林省磐石经济开发区西点大街 777 号 关于公司抗病毒片获得药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于近日收到国 家药品监督管理局（以下简称"国家药监局"）签发的抗病毒片《药品补充申请 批准通知书》。现将相关情况公告如下： 一、药品的基本情况 生产企业地址：吉林省吉林市磐石市英联大街 777 号 证书编号：2025B01062 药品批准文号：国药准字 Z19991079 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 此次申请事项符合药品注册的有关要求，同意按照《药品上市后变更管理办法（试 行）》相关规定，批准本品上市许可持有人由"磐石巨康药业有限公司（地址： 吉林省吉林市磐石市英联大街 ...

吉林省西点药业科技发展股份有限公司 关于使用部分闲置募集资金进行现金管理和部分闲置自有资金 进行委托理财到期赎回并继续进行现金管理和委托理财的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 1 月 20 日召开第八届董事会第十次会议、第八届监事会第十次会议，分别审议通 过了《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现 金管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和 资金安全的前提下，使用额度不超过人民币 1.0 亿元的部分闲置募集资金（含超 募资金）进行现金管理，公司及全资子公司在确保不影响公司日常经营的前提下， 使用额度不超过人民币 1.5 亿元的部分闲置自有资金进行现金管理和委托理财， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自董事会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可循 环滚动使用。具体内容详见公司在巨潮资讯网上披露的《关于使用部分闲置募集 资金进行现金管理及使用部分闲 ...